

www.cardiorenal2020.gr

12th Symposium

Cardiovascular Disease and Renal Dysfunction 2020

with international participation

Saturday

January 18, 2020

Eugenides Foundation,
Athens, Greece

Friday

January 17, 2020

Workshop 1

Tips on Heart and kidneys ultrasound

Workshop 2

Diabetes mellitus in the era of integrated cardiovascular and renal care

Organization:



Under the auspices of:



University of Athens,
Medical School, Athens, Greece



ΕΛΛΗΝΙΚΗ ΚΑΡΔΙΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ
HELLENIC CARDIOLOGICAL SOCIETY



European
Society of
Hypertension

Final Program



ORIZAL PLUS[®]

Olmesartan Medoxomil, Amlodipine Besilate, Hydrochlorothiazide



ORIZAL[®]

Olmesartan Medoxomil, Amlodipine Besilate



Περισσότερα πληροφορίες διατίθενται από τον κάτοχο της άδειας κυκλοφορίας κατόπιν αιτήσεως.



Menarini Hellas

Menarini Hellas A.E. - Av. Δαμβέργη 7, 104 45 Αθήνα, Τ.: 210 8316111-13, F.: 210 8317343, info@menarini.gr

Cardiovascular Disease and Renal Dysfunction 2020

with international participation

Dear Colleagues,

I cordially welcome you to the 12th Symposium on “**Cardiovascular Disease and Renal Dysfunction 2020**” with international participation, which is held in Athens, at the Eugenides Foundation, on January 17-18, 2020.

The Symposium “Cardiovascular Disease and Renal Dysfunction 2020” is an effort to enhance the interchange of emerging new information on pathophysiological and clinical interrelationships between kidneys, the heart and the vasculature.

During the Symposium we will have the opportunity to attend Sessions with the participation of world experts, who are pioneers in the field of cardiovascular research. Through Round Table discussions and Debates, the Symposium offers an outstanding Scientific Program, featuring both state-of-the-art knowledge and innovative approaches of the patient with renal impairment and cardiovascular disease.

We anticipate that this Symposium will be valuable in terms of both everyday clinical practice and advanced research.


We look forward to providing you with the famous Greek hospitality, in what promises to be an exciting scientific event.

Sincerely,



Dimitrios Tousoulis

Chairman of the Organizing Committee
Professor of Cardiology
Director, 1st Department of Cardiology
Athens University Medical School
“Hippokration” Hospital, Athens, Greece



Konstantinos Tsioufis

Co-Chairman of the Organizing Committee
Professor of Cardiology
1st Department of Cardiology
Athens University Medical School
“Hippokration” Hospital, Athens, Greece

Symposium Chairman:

Dimitrios Tousoulis

Professor of Cardiology, Director of the 1st Department of Cardiology, Athens University Medical School, "Hippokration" Hospital, Athens, Greece

Symposium Co-Chairman:

Konstantinos Tsioufis

Professor of Cardiology, 1st Department of Cardiology, Athens University Medical School, "Hippokration" Hospital, Athens, Greece
President of Hellenic Cardiological Society (2017-18)
President of European Society of Hypertension (2018-19)

International Invited Faculty

Bakris George

Professor of Medicine, University of Chicago Hospitals, Director of Hypertension Diseases Unit, Chicago IL, USA

Papademetriou Vassilios

Professor of Medicine (Cardiology), Georgetown University, Director Interventional Hypertension and Vascular Medicine Program, VA Medical Center, Washington DC, USA



General Information

Scientific Secretariat

1st Department of Cardiology, Athens University Medical School

“Hippokration” Hospital

114, Vas. Sofias Ave., GR 115 27 Athens, Greece

Tel.: +30 213 20 88 099, Fax: +30 213 20 88 676

E-mail: ktsioufis@hippocratio.gr, Web-site: www.cardiorenal2020.gr

Organizing Secretariat

THE MASTERMIND GROUP

26, Marathonomahon Str., GR 151 24 Maroussi, Greece

Tel.: +30 210 68 27 405, Fax: +30 210 68 27 409

E-mail: dpanakoulia@tmg.gr, Web-site: www.tmg.gr

Symposium Date

January 17-18, 2020

Symposium Venue

Eugenides Foundation

387, Syggrou Ave., GR 175 64 Athens, Greece

Tel.: +30 210 94 69 600, Fax: +30 210 94 17 372

Registration

Registration to the Symposium is free.

Official Language

The official languages of the Symposium are greek and english.

Certificate of Attendance

All registered participants will receive a Certificate of Attendance from the Symposium Secretariat, after the end of the Scientific Program.

Accreditation

The Symposium is accredited by the Greek Medical Association for **16 hours of External CME Credits**.

Friday, January 17th, 2020

*Practical Workshop on Cardiac and kidney ultrasound:
An Updated Fast-Track Course of The Master on "Arterial Hypertension and Related Cardiovascular
and Renal Disease" of Medical School of National and Kapodistrian University of Athens*

08.45 **Welcome address**

Workshop I**Tips on Heart and kidney ultrasound**

09.00-11.00 **Tips on kidney ultrasound**
Coordinators: S. Marinaki, D. Petras
Operators: D. Konstantinidis, N. Liasis

11.00-13.00 **Tips on Heart Ultrasound**
Coordinators: K. Aggeli, S. Brili, I. Oikonomidis
Operators: A. Kasiakogias, D. Klettas, E. Oikonomou

13.00-13.30 **Coffee break**

Workshop II**Diabetes mellitus in the era of integrated cardiovascular and renal care**

13.30-14.30 **Short Presentations I: The best article of 2019 related to Diabetes and Cardiovascular Disease**
Chairmen: A. Alexopoulou, C. Pitsavos, A. Raptis

13.31-13.36 *Diabetes mellitus and heart failure*
E. Andrikou

13.37-13.42 *Revascularization of a diabetic patient with coronary artery disease*
K. Kintis

13.43-13.48 *Diabetes mellitus and peripheral artery disease*
F. Sigala

13.49-13.54 *Diabetes mellitus and atrial fibrillation*
A. Kordalis

13.55-14.00 *Anti-platelet treatment in primary prevention of cardiovascular disease?*
D. Konstantinidis

14.01-14.06 *Diabetes mellitus and hypertriglyceridemia*
V. Katsi

14.07-14.12 *Diabetes mellitus and hyperuricemia*
K. Massoura

14.13-14.30 *Comments-Discussion: D. Roussos, M. Zaromytidou, K. Konstantinou, G. Trantalís, G. Marinos, P. Tolis, A. Milkas*

Friday, January 17th, 2020**14.30-15.30 Short Presentations II: The best article of 2019 related to Diabetes and cardiovascular disease**

Chairmen: A. Androulakis, S. Foussas, I. Kyriazis

14.31-14.36 *Diabetes mellitus and blood pressure variability*
N. Magkas14.37-14.42 *Diabetes mellitus and erectile dysfunction*
N. Ioakeimidis14.43-14.48 *Glucose reduction and cardiovascular benefits in diabetes mellitus. The modulating role of blood pressure*
G. Bazoukis14.49-14.54 *Diabetes mellitus and hypertrophic cardiomyopathy*
I. Liatakis14.55-15.00 *Vascular calcification in diabetes mellitus*
C. Georgakopoulos15.01-15.06 *Subclinical inflammation and diabetes mellitus*
S. Tsalamandris15.07-15.30 *Comments-Discussion: G. Viogatzis, I. Karapati, D. Papoutsis, A. Aggelis, K. Damianaki, R. Katsarou***15.30-15.45 Coffee break****15.45-16.45 Meet the experts**

Chairmen: Ant. Manolis, A. Melidonis

15.46-15.56 *How to monitor renal function in patients with diabetes mellitus in clinical practice?*
K. Makrylakis15.57-16.07 *Main developments in the treatment of diabetic neuropathy and diabetic foot*
N. Papanas16.08-16.18 *Cardioprotective mechanisms of GLP-1 receptor agonists*
I. Ioannidis16.19-16.29 *Hypoglycemia and cardiovascular effects*
A. Thanopoulou16.30-16.45 *Comments: S. Pappas, A. Alaveras, A. Pittaras*

Friday, January 17th, 2020**16.45-17.45 Challenges in the daily clinical practice that need further clarification**

Chairmen: I. Kallikazaros, T. Makris

16.46-16.56 *Diabetes-related cardiomyopathy*
S. Liatis16.57-17.07 *Non alcoholic hepatic steatosis in diabetic and hypertensive patients*
E. Cholongitas17.08-17.18 *Optimal blood pressure target is <140/90 in chronic kidney disease*
H. Grassos17.19-17.29 *RASS blockers in chronic kidney disease. When to stop and when to re-start*
D. Papadopoulos17.30-17.45 *Comments:* A. Papanikolaou, F. Lagiou, M. Papavasileiou,
M. Kallistratos**17.45-18.15 Satellite Lecture****18.15-18.30 Coffee break****18.30-19.00 Satellite Lecture****19.00-20.15 New ESC Guidelines on Diabetes Mellitus: An Update**

Chairmen: G. Dimitriadis, N. Tentolouris

19.01-19.13 *Diagnostic aspects*
E. Chatziaggelaki19.14-19.26 *Prevention of cardiovascular disease in diabetic patients*
A. Kokkinos19.27-19.39 *Heart failure and diabetes*
G. Siasos19.40-19.52 *The dos and don'ts of diabetes care according to the new ESC guidelines*
V. Lampadiari19.53-20.15 *Comments:* M. Noutsou, A. Lepouras, A. Mariolis, I. Eleftheriadou

Saturday, January 18th, 2020

08.30	Welcome address D. Tousoulis, Chairman of the Symposium K. Tsioufis, Co-Chairman of the Symposium
08.45-10.00	Round Table: "Use of drugs and nephrotoxic substances in patients with cardiorenal disease" Chairmen: D. Alexopoulos, D. Goumenos
08.46-08.56	<i>Use of diuretics</i> V. Liakopoulos
08.57-09.07	<i>An update on the management of hyperkalemia</i> E. Papachristou
09.08-09.18	<i>Contrast-induced nephropathy in Interventional Cardiology</i> A. Zacharoulis
09.19-09.29	<i>Cardiovascular drugs in patients with renal dysfunction</i> A. Damelou
09.30-10.00	<i>Comments: L. Poulimenos, H. Triantafyllidi, M. Sonikian, G. Tsouka</i> <i>Discussion with the audience</i>
10.00-10.39	Special session: "Focus on cardiorenal syndrome" Chairman: P. Pasadakis
10.02-10.14	<i>Acute Cardiorenal syndrome type 1</i> I. Parissis
10.15-10.27	<i>Cardiorenal syndrome type 4</i> A. Papagianni
10.28-10.34	<i>Comments: A. Karavidas, E. Donoussi</i>
10.35-10.39	<i>Discussion</i>
10.40-11.30	Lectures Chairman: J. Goudevenos, I. Stefanidis
10.42-10.57	<i>Diuretic resistance in heart failure</i> F. Triposkiadis
10.58-11.13	<i>Are SGLT2 inhibitors diuretics of the proximal tubule?</i> D. Vlachakos
11.14-11.29	<i>Volume regulation for BP control in hemodialysis - Focus on recent evidence</i> P. Sarafidis
11.30-11.50	Coffee break

Saturday, January 18th, 2020

11.50-13.10 **Special Session: "The Hellenic cardio-renal community meets the experts. The challenge of decreasing cardiovascular mortality in chronic kidney disease patients"**

Co-ordinators: D. Tousoulis, K. Tsioufis, P. Zebekakis

11.51-12.03 *Role of SGLT2 inhibitors as cardiorenal risk reducing agents*
G. Bakris

12.04-12.16 *Could Renal denervation reduce cardiovascular risk?*
V. Papademetriou

12.17-12.29 *Cardiovascular protection by antihypertensive drugs. Are there really any differences?*
C. Thomopoulos

12.30-12.42 *Best method for blood pressure measurement in the patient with chronic kidney disease*
G. Stergiou

12.43-12.55 *Chronic stable coronary artery disease in patients with chronic kidney disease*
Ath. Manolis

12.56-13.10 *Discussion with the audience*

13.10-13.40 **Satellite Lecture**

13.40-14.40 **Round Table: «Patient with cardio-renal disease and comorbidities. What the cardiologist/nephrologist should know in case of»**

Chairman: I. Bolletis, D. Boumbas

13.41-13.53 *Liver cirrhosis*
I. Koskinas

13.54-14.06 *Infection in the Critical care unit*
G. Dimopoulos

14.07-14.19 *Rheumatic disease with cardiovascular effects*
D. Vassilopoulos

14.20-14.32 *Nonsteroidal anti-inflammatory drugs and the need for gastroprotection*
G. Papatheodoridis

14.33-14.40 *Comments: E. Sanidas, G. Latsios, K. Aznaouridis, P. Stougiannos*

14.40-15.10 **Satellite Lecture**

15.10-15.40 **Break - light lunch**

Saturday, January 18th, 2020**15.40-17.00 Workshop on lipids: Tailoring the cardiorenal protection by LDL lowering treatments: A deep dive in the new ESC 2019 guidelines**Coordinator: **K. Tsioufis**Chairman: **I. Skoumas, A. Spanos**15.41-15.53 *Tackling high LDL in CKD: Where do we stand?*
G. Kolovou15.54-16.06 *Combination lipid-lowering therapy 2020: Available data and clinical tips*
L. Rallidis16.07-16.19 *PCSK9 inhibitors in everyday practice: The "how to's"*
D. Richter16.20-16.32 *Targets for lipid-lowering therapy apart from LDL*
C. Vlachopoulos16.33-16.45 *Safety and efficacy of statins in patients with CKD/on hemodialysis*
R. Kalaitzidis16.46-17.00 *Discussion with the audience***17.00-18.15 Hot issues in the management of patients with cardio-renal disease**Chairman: **E. Iliodromitis, C. Karvounis, V. Pyrgakis**17.01-17.09 *What's new in anticoagulation therapy, in patients with atrial fibrillation and CKD or on dialysis*
V. Vasilikos17.10-17.18 *What's new in the type/duration of antiplatelet treatment in patients with CKD post PCI*
D. Tziakas17.19-17.27 *Pulmonary hypertension in a patient with CKD*
I. Paraskevaidis17.27-17.36 *Atrial fibrillation in CKD: Is it time for ablation?*
D. Tsiachris17.37-17.45 *Leadless pacemaker as the best solution*
S. Sideris17.46-17.54 *Chest pain in a patient on dialysis*
J. Kanakakis17.55-18.15 *Comments:* **N. Kafkas, A. Avgeropoulou, P. Dilaveris, S. Papaioannou, G. Katsimagklis****18.15-18.30 Coffee break**

Saturday, January 18th, 2020**18.30-19.45 Round Table: "Heart failure in the patient with renal disease: The double-edged sword"**

Chairman: Th. Apostolou, S. Patsilidakos, A. Trikas

18.31-18.39 *Hyponatremia and water balance disorders*
D. Farmakis18.40-18.48 *Hyperkalaemia: A clinical perspective*
C. Chrysochoou18.49-18.57 *Definition of acute kidney injury in the cardiac patient*
D. Petras18.58-19.06 *The conundrum of treating gout in patients with CKD*
G. Lazaros19.07-19.15 *Should dialysis be done before death in the elderly with advanced CKD?*
S. Marinaki19.16-19.24 *Low level of vitamin D*
D. Aggelousi19.25-19.45 *Comments-Discussion: N. Kaperonis, A. Gouziouta, G. Triantafyllis, I. Skiadas, T. Hiras, A. Kitsiou***19.45-21.00 Interventional therapies from hypertension to heart failure**

Chairman: C. Stefanadis, E. Tsiamis

19.46-19.54 *Renal artery stenting*
K. Dimitriadis19.55-20.03 *Renal denervation for hypertension*
M. Doumas20.04-20.12 *Aortic neuromodulation for heart failure*
D. Syrseloudis20.13-20.21 *TAVI*
K. Toutouzas20.22-20.30 *Mitral and tricuspid transcatheter interventions*
E. Vavouranakis20.31-20.39 *Complex coronary artery disease*
P. Davlouros20.40-20.55 *Surgeon's view: J. Chlorogiannis, N. Baikousis, K. Perreas, D. Nikas, G. Pattakos, C. Kotoulas*20.56-21.00 *Discussion with the audience***21.00 Conclusion**

K. Tsioufis



edarbi®

azilsartan medoxomil



ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Edarbi 20 mg δισκία Edarbi 40 mg δισκία Edarbi 80 mg δισκία **2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΩΤΙΚΗ ΣΥΝΘΕΣΗ:** Edarbi 20 mg δισκία: Κάθε δισκίο περιέχει 20 mg μεδοξομιλικής αζιλσартάνης (ως κάλιο). Edarbi 40 mg δισκία: Κάθε δισκίο περιέχει 40 mg μεδοξομιλικής αζιλσартάνης (ως κάλιο). Edarbi 80 mg δισκία: Κάθε δισκίο περιέχει 80 mg μεδοξομιλικής αζιλσартάνης (ως κάλιο). Για τον πλήρη κατάλογο των εκδόσεων, βλ. παράγραφο 6.1. **3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Δισκίο. Edarbi 20 mg δισκία: Λευκό έως σχεδόν λευκό στρογγυλό δισκίο, διαμέτρου 7,6 mm, με ανάγλυφο το "ASL" από τη μια πλευρά και "20" από την άλλη. Edarbi 40 mg δισκία: Λευκό έως σχεδόν λευκό στρογγυλό δισκίο, διαμέτρου 9,6 mm, με ανάγλυφο το "ASL" από τη μια πλευρά και "40" από την άλλη. Edarbi 80 mg δισκία: Λευκό έως σχεδόν λευκό στρογγυλό δισκίο, διαμέτρου 9,6 mm, με ανάγλυφο το "ASL" από τη μια πλευρά και "80" από την άλλη. **7. ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** Takeda Pharma A/S Dybendal Alle 10, 2630 Taastrup Δανία **10. ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** 20-03-2018. Λεπτομερείς πληροφορίες για το παρόν φαρμακευτικό προϊόν είναι διαθέσιμες στον δικτυακό τόπο του Ευρωπαϊκού Οργανισμού Φαρμάκων: <http://www.ema.europa.eu> **ΤΡΟΠΟΣ ΔΙΑΒΑΣΗΣ (για Ελλάδα):** Φαρμακευτικό προϊόν για το οποίο απαιτείται ειδική ιατρική συνταγή. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ**

Περιεκτικότητα	Συσκευασία	Νοσοκομειακή Τιμή	Λιανική Τιμή
EDARBI 40 mg	BT x 28 TABS	10,15 €	16,07 €
EDARBI 80 mg	BT x 28 TABS	16,04 €	25,41 €



BIANEX Α.Ε. ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

Γραφεία Επιστημονικής Ενημέρωσης

ΑΘΗΝΑ: Οδός Τατοΐου 146 71 Ν. Ερυθραία, Τηλ.: 210 8009111

• **E-Mail:** mailbox@vianex.gr • **INTERNET:** <http://www.vianex.gr>

ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδημίου 113, Κόμβος Μακρυγιάννη

Εύσμος Θεσσαλονίκης, ΤΚ 56224, Τηλ.: 2310 861683



Takeda Pharma A/S

Dybendal Alle 10, 2630 Taastrup
Δανία

Επιτρέπεται να γίνουν τα φάρμακα που αναφέρονται
Αναφορά
DMLC της αναθεώρησης σύμφωνα με
ΟΔΕ της φαρμάκου
Συμβαλλόμενος του «ΣΤΗΝΗ ΚΑΡΤΑ»

VE19253EDA/1-10/2019

Curilen®

Bisoprolol fumarate + Acetylsalicylic acid

Βισοπρολόλη
5 mg / 10 mg

Ακετυλοσαλικυλικό οξύ
100 mg



Pharmaceutical Laboratories S.A.